Krishna R. Polu

Krishna R.
Polu was the founder of Expedition Therapeutics, Inc., founded in 2017, where the title held was Chief Executive Officer from 2017 to 2018.
Dr. Polu is also the founder of Lassen Therapeutics LLC,R1 Therapeutics, Inc...
Dr. Polu currently holds the position of Principal at Red Tree Venture Capital since 2021.
Former positions include Chief Executive Officer at Scout Bio, Inc. in 2018; Chief Executive Officer at Commit Biologics ApS from 2023 to 2025; Executive Director-Global Development at Amgen, Inc. from 2007 to 2009; Director at Goldilocks Therapeutics, Inc.; Independent Director at Frazier Lifesciences Acquisition Corp.; Vice President-Clinical Development at Affymax, Inc. from 2009 to 2013; Chief Medical Officer at CytomX Therapeutics Holdings LLC from 2013 to 2014; Chief Medical Officer at Horizon Pharmaceutical LLC from 2015 to 2016; Chief Medical Officer at Raptor Pharmaceuticals, Inc. from 2015 to 2016; Chief Medical Officer at CytomX Therapeutics, Inc. from 2013 to 2014; and Chief Medical Officer, EVP-Research & Development at Equillium, Inc. in 2020.
Education includes undergraduate studies at Stanford University and a doctorate from Texas University of Health Center at San Antonio.